US0453961080 - Common Stock
11.34 -0.05 (-0.44%)
ASSEMBLY BIOSCIENCES INC
NASDAQ:ASMB (2/22/2024, 12:22:04 PM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2010-12-17. Its hepatitis B virus (HBV) pipeline includes potent, HBV core inhibitors in clinical development, which are designed to disrupt the virus replication cycle at several key points with a focus on achieving finite treatment and functional cures. Its HBV and hepatitis delta virus (HDV) pipeline also includes two complementary approaches: a viral entry inhibitor and an oral, liver-focused, interferon-alpha receptor agonist, with potential application for both HBV and as chronic suppressive therapy for HDV, which is associated with increased disease burden for HBV/HDV patients. The herpesvirus pipeline addresses two serious consequences associated with herpesvirus infections, high-recurrence genital herpes and transplant-associated herpesviruses. Its HBV and HDV programs include ABI-4334 (4334), ABI-5366 (5366), HBV/HDV inhibitor program, and others.
ASSEMBLY BIOSCIENCES INC
Two Tower Place, 7Th Floor
South San Francisco CALIFORNIA 94080
CEO: John G. McHutchison
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
These stocks are gapping in today's session
Assembly Biosciences announces a reverse stock split to bring the company into compliance with Nasdaq listing requirements.
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 ...
Here you can normally see the latest stock twits on ASMB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.